Indication for testing | Presumed GH sufficient short stature (GH ≥ 10 μg/L) | Possible GHD (GH < 10 μg/L) | Concern for multiple pituitary abnormalities | Neoplasm with risk to pituitary | Exogenous glucocorticoid exposure | Known multiple pituitary abnormalities | p-valuea |
---|---|---|---|---|---|---|---|
n | 35 | 33 | 52 | 50 | 35 | 17 | Â |
Baseline cortisol (nmol/L) | 231.0 (124.3) | 203.3 (136.6) | 221.1 (182.0) | 199.1 (119.4) | 145.7 (139.8) | 202.2 (139.6) | 0.18 |
Delta cortisol (nmol/L) | 454.9 (168.1) | 485.2 (139.7) | 399.8 (160.4) | 470.2 (189.2) | 215.9 (218.4) | 349.6 (219.5) | <0.0005 |
Peak cortisol (nmol/L) | 685.9 (161.8) | 688 .5 (179.8) | 620.9 (178.6) | 675.8 (138.5) | 373.2 (246.1) | 552.2 (227.0) | <0.0005 |
Baseline ACTH (pmol/L) | 3.2 (1.8) | 5.9 (6.6) | 4.2 (2.6) | 3.6 (1.9) | 3.7 (4.1) | 4.7 (2.8) | 0.036 |
Delta ACTH (pmol/L) | 14.9 (9.3) | 23.0 (18.5) | 13.2 (11.6) | 21.4 (26.6) | 6.3 (4.9) | 18.3 (25.6) | 0.0007 |
Peak ACTH (pmol/L) | 18.1 (9.6) | 28.9 (17.9) | 17.4 (11.5) | 25.0 (27.0) | 10.1 (7.5) | 23.0 (26.3) | 0.0003 |
Failure Rate (peak cortisol < 500 nmol/L) | 11.4 % | 9.1 % | 21.2 % | 6.0 % | 62.9 % | 29.4 % | <0.0005 |